search
Back to results

Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries

Primary Purpose

Spinal Cord Injury

Status
Suspended
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Autologous Incubated Macrophages (cell therapy)
Sponsored by
Proneuron Biotechnologies
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Cord Injury focused on measuring paraplegia, quadraplegia, tetraplegia, paralysis, nerve regeneration, Acute, Complete SCI

Eligibility Criteria

16 Years - 65 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Traumatic SCI during last 14 days Age 16 to 65 years Complete spinal cord injury (ASIA A) Neurological level : C5 to T11 MRI showing lesion Exclusion Criteria: Women who are pregnant or breastfeeding Coma or other severe injury or disease Penetrating injury Ongoing mechanical ventilation Unsuitable based on MRI or other factor

Sites / Locations

  • Craig Hospital
  • Shepherd Center
  • UMDNJ
  • Kessler Medical Rehabilitation Research and Education Corporation
  • Mount Sinai Spinal Cord Injury Model System
  • Shriners Hospital for Children
  • Chaim Sheba Medical Center

Outcomes

Primary Outcome Measures

Improvement of ASIA grade

Secondary Outcome Measures

Sensory scores
Motor scores
Bladder and bowel function

Full Information

First Posted
December 10, 2003
Last Updated
August 27, 2009
Sponsor
Proneuron Biotechnologies
Collaborators
The Marcus Foundation, B.I.R.D. (Israel-U.S. Binational Industrial Research and Development)
search

1. Study Identification

Unique Protocol Identification Number
NCT00073853
Brief Title
Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries
Official Title
A Phase II Multicenter, Randomized-Controlled Study to Evaluate the Safety and Efficacy of Autologous Incubated Macrophages for the Treatment of Patients With Complete Spinal Cord Injuries
Study Type
Interventional

2. Study Status

Record Verification Date
March 2006
Overall Recruitment Status
Suspended
Study Start Date
September 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Proneuron Biotechnologies
Collaborators
The Marcus Foundation, B.I.R.D. (Israel-U.S. Binational Industrial Research and Development)

4. Oversight

5. Study Description

Brief Summary
Autologous Incubated Macrophages (ProCord) is being developed as a therapy for acute, complete spinal cord injury (SCI). The therapy is intended to reverse the loss of motor and sensory function. Following non-CNS tissue injury, macrophages quickly arrive on the scene, where they clean up cell debris, secrete different molecules thus promoting a controlled inflammatory reaction that forms the first phase of the wound healing process. While this process occurs in most tissues, including peripheral nerves, it does not occur in the CNS, where macrophages and other immune cells are relatively rare, and their activities curtailed by a biochemical mechanism known as "immune privilege." In animal studies, it appears that incubated macrophages circumvent the immune privilege, thus supporting the regrowth of axons through the injury site and enabling the recovery of neurological function. The concept derives from the pioneering research of Prof. Michal Schwartz at the Weizmann Institute of Science.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injury
Keywords
paraplegia, quadraplegia, tetraplegia, paralysis, nerve regeneration, Acute, Complete SCI

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
61 (false)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
Autologous Incubated Macrophages (cell therapy)
Primary Outcome Measure Information:
Title
Improvement of ASIA grade
Secondary Outcome Measure Information:
Title
Sensory scores
Title
Motor scores
Title
Bladder and bowel function

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Traumatic SCI during last 14 days Age 16 to 65 years Complete spinal cord injury (ASIA A) Neurological level : C5 to T11 MRI showing lesion Exclusion Criteria: Women who are pregnant or breastfeeding Coma or other severe injury or disease Penetrating injury Ongoing mechanical ventilation Unsuitable based on MRI or other factor
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Lammertse, M.D.
Organizational Affiliation
Craig Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Nachshon Knoller, M.D.
Organizational Affiliation
Chaim Sheba Medical Center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Marca Sipski, M.D.
Organizational Affiliation
University of Miami
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Edward Benzel, M.D.
Organizational Affiliation
The Cleveland Clinic
Official's Role
Study Director
Facility Information:
Facility Name
Craig Hospital
City
Englewood
State/Province
Colorado
ZIP/Postal Code
80110
Country
United States
Facility Name
Shepherd Center
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30309
Country
United States
Facility Name
UMDNJ
City
Newark
State/Province
New Jersey
ZIP/Postal Code
07103
Country
United States
Facility Name
Kessler Medical Rehabilitation Research and Education Corporation
City
West Orange
State/Province
New Jersey
ZIP/Postal Code
07052
Country
United States
Facility Name
Mount Sinai Spinal Cord Injury Model System
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Shriners Hospital for Children
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Facility Name
Chaim Sheba Medical Center
City
Tel Hashomer
ZIP/Postal Code
52621
Country
Israel

12. IPD Sharing Statement

Citations:
PubMed Identifier
16235699
Citation
Knoller N, Auerbach G, Fulga V, Zelig G, Attias J, Bakimer R, Marder JB, Yoles E, Belkin M, Schwartz M, Hadani M. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine. 2005 Sep;3(3):173-81. doi: 10.3171/spi.2005.3.3.0173.
Results Reference
background
PubMed Identifier
14512160
Citation
Bomstein Y, Marder JB, Vitner K, Smirnov I, Lisaey G, Butovsky O, Fulga V, Yoles E. Features of skin-coincubated macrophages that promote recovery from spinal cord injury. J Neuroimmunol. 2003 Sep;142(1-2):10-6. doi: 10.1016/s0165-5728(03)00260-1.
Results Reference
background
PubMed Identifier
9662373
Citation
Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Yoles E, Fraidakis M, Solomon A, Gepstein R, Katz A, Belkin M, Hadani M, Schwartz M. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med. 1998 Jul;4(7):814-21. doi: 10.1038/nm0798-814.
Results Reference
background
PubMed Identifier
22525310
Citation
Lammertse DP, Jones LA, Charlifue SB, Kirshblum SC, Apple DF, Ragnarsson KT, Falci SP, Heary RF, Choudhri TF, Jenkins AL, Betz RR, Poonian D, Cuthbert JP, Jha A, Snyder DA, Knoller N. Autologous incubated macrophage therapy in acute, complete spinal cord injury: results of the phase 2 randomized controlled multicenter trial. Spinal Cord. 2012 Sep;50(9):661-71. doi: 10.1038/sc.2012.39. Epub 2012 Apr 24.
Results Reference
derived

Learn more about this trial

Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries

We'll reach out to this number within 24 hrs